The DOI matches its Crossref record; 314 of the 318 references it cites were found in a registry or an index.
Self-assembled mRNA vaccines
Open accessAbstract
mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology, and nanotechnology have generated interest in delivering safe and effective mRNA therapeutics. In this review, we discuss design and self-assembly of mRNA vaccines. Self-assembly, a spontaneous organization of individual molecules, allows for design of nanoparticles with customizable properties. We highlight the materials commonly utilized to deliver mRNA, their physicochemical characteristics, and other relevant considerations, such as mRNA optimization, routes of administration, cellular fate, and immune activation, that are important for successful mRNA vaccination. We also examine the COVID-19 mRNA vaccines currently in clinical trials. mRNA vaccines are ready for the clinic, showing tremendous promise in the COVID-19 vaccine race, and have pushed the boundaries of gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, one copy of saRNA produces multiple copies of RNA transcripts by the above-described mechanism to initiate self-amplification of antigen genes in the cell.35,195,196”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [35]
In the citing paper
“Hence, the delivery vector employed in saRNA vaccines must allow for higher loading capacity and encapsulation efficiency.35”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [35]
In the citing paper
“Tfh cells recognize antigens on the APC surface and help to activate B cells, which in turn produce high-affinity virus-neutralizing antibodies.6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [56]
In the citing paper
“Tfh cells further help activate CD8+ cytotoxic T cells that may specifically recognize and eliminate virus-infected cells (Figure 1).6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [56]
In the citing paper
“These lipids can improve nanoparticle properties, such as particle stability, delivery efficacy, tolerability and biodistribution7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“In addition to cationic or ionizable lipids, lipid nanoparticle–mRNA formulations typically contain other lipid components, such as phospholipids (for example, phosphatidylcholine and phosphatidylethanolamine), cholesterol or polyethylene glycol (PEG)-functionalized lipids (PEG-lipids)7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“This structural feature protects mRNA molecules from nuclease degradation and increases nanoparticle stability in physiological fluids17,46.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Lipid nanoparticle–mRNA formulations manufactured by rapid mixing exhibit a stable nanostructure17,130,131, in which mRNA molecules can be encapsulated in the interior core through electrostatic interactions with the lipids17,131.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Incorporating PEG-lipids further decreases recognition by the MPS and clearance by renal filtration17,127.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“This technique allows reproducible and scalable production of lipid nanoparticle–mRNA formulations that show high encapsulation efficiency and homogeneous size distribution17,131.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“mRNA-1273 is stored at −15 °C to −20 °C and is directly injected after thawing17, whereas BNT162b2 is stored at −60 °C to −80 °C and requires thawing and dilution by saline before injection17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“mRNA-1273 is stored at −15 °C to −20 °C and is directly injected after thawing17, whereas BNT162b2 is stored at −60 °C to −80 °C and requires thawing and dilution by saline before injection17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Of note, the authorized COVID-19 mRNA vaccines are both stored in freezing conditions in the presence of sucrose17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“The IVT mRNA molecules used in the mRNA-1273 and BNT162b2 COVID-19 vaccines were prepared by replacing uridine with m1ψ17,19,21, and their sequences were optimized to encode a stabilized pre-fusion spike protein with two pivotal proline substitutions17,19,21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“For example, the clinical-grade COVID-19 vaccine, mRNA-1273, was produced within a month after the SARS-CoV-2 genome sequence was available15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“About 2, 5 and 6 months from sequence availability, clinical trial phases I, II and III were initiated, respectively15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Finally, mRNA-1273 obtained Emergency Use Authorization from the FDA and conditional marketing authorization from the EMA within a year15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“These features make lipid nanoparticle–mRNA formulations a flexible and on-demand vaccine platform to rapidly respond to emerging infectious pathogens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“First, mRNA is a non-infective and non-integrating agent with the ability to encode a broad range of antigens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Since then, lipid nanoparticle–mRNA formulations have emerged as a potent alternative to conventional vaccine platforms, owing to their unique features4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Finally, GMP-grade lipid nanoparticle-mRNA vaccines can be manufactured for specific antigens in a short period of time, compared with other vaccine platforms, such as recombinant proteins and inactivated vaccines2,4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Whitesides, G. M., & Grzybowski, B. A. (2002) · Science · doi:10.1126/science.1070821 · Cited by 7,550
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., RINGOLD, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,954
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Research works printed but not linked: 3
- Walsh, 2020, Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates, N. Engl. J. Med., 10.1056/NEJMoa2027906 · DOI · Paper page
- Tanaka, 2020, Self-degradable lipid-like materials based on “hydrolysis accelerated by the intra-particle enrichment of reactant (HyPER)” for messenger RNA delivery, Adv. Funct. Mater., 34, 1910575, 10.1002/adfm.201910575 · DOI · Paper page
- Mulligan, 2020, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, Nature, 586, 589, 10.1038/s41586-020-2639-4 · DOI · Paper page
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 917
Self-citationmRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y. A., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 776
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 506
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
Dynamic and reconfigurable materials from reversible network interactions
Webber, M. J., & Tibbitt, M. W. (2022) · Nature Reviews Materials · doi:10.1038/s41578-021-00412-x · Cited by 424
Overcoming barriers by local drug delivery with liposomes
Antimisiaris, S. G., Marazioti, A., Kannavou, M., Natsaridis, E., Gkartziou, F., Kogkos, G., & Mourtas, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.019 · Cited by 339
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation
Kim, J., Jozić, A., Lin, Y., Eygeris, Y., Bloom, E., Tan, X., Acosta, C., MacDonald, K. D., Welsher, K., & Sahay, G. (2022) · ACS Nano · doi:10.1021/acsnano.2c05647 · Cited by 292
Self-citationNanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. K. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 276
Lipid nanoparticles in the development of mRNA vaccines for COVID-19
Wilson, B., & Geetha, K. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103553 · Cited by 265
PEGylated therapeutics in the clinic
Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10600 · Cited by 247
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 243
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines
Swetha, K., Kotla, N. G., Tunki, L., Jayaraj, A., Bhargava, S. K., Hu, H., Bonam, S. R., & Kurapati, R. (2023) · Vaccines · doi:10.3390/vaccines11030658 · Cited by 196
Nucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 225
Nanomaterials Synthesis through Microfluidic Methods: An Updated Overview
Niculescu, A.-G., Chircov, C., Bîrcă, A. C., & Grumezescu, A. M. (2021) · Nanomaterials · doi:10.3390/nano11040864 · Cited by 176
Recent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187
Kumari, M., Lu, R., Li, M., Huang, J., Hsu, F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00852-9 · Cited by 166
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 160
Self-citationmRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 158
Ben‐Akiva, E., Karlsson, J. E., Hemmati, S., Yu, H., Tzeng, S. Y., Pardoll, D. M., & Green, J. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301606120 · Cited by 145
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 141
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
Mendonça, M. C. P., Kont, A., Kowalski, P. S., & O’Driscoll, C. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103505 · Cited by 143
mRNA nanomedicine: Design and recent applications
Kubiatowicz, L. J., Mohapatra, A., Krishnan, N., Fang, R. H., & Zhang, L. (2022) · Exploration · doi:10.1002/exp.20210217 · Cited by 131
Lipid carriers for mRNA delivery
Zhang, W., Jiang, Y., He, Y., Boucetta, H., Wu, J., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.026 · Cited by 134
Quality by Design for enabling RNA platform production processes
Daniel, S., Kis, Z., Kontoravdi, C., & Shah, N. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.03.012 · Cited by 129
The nano delivery systems and applications of mRNA
Li, M., Li, Y., Li, S., Jia, L., Wang, H., Li, M., Deng, J., Zhu, A., Ma, L., Li, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113910 · Cited by 127
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 122
Macropinocytosis: Biology and mechanisms
Kay, R. R. (2021) · Cells and Development · doi:10.1016/j.cdev.2021.203713 · Cited by 124
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124
Lipid nanoparticles: Composition, formulation, and application
Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 115
Haghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 125
Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles
Piperno, A., Sciortino, M. T., Giusto, E., Montesi, M., Panseri, S., & Scala, A. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s321329 · Cited by 97
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 98
Sustained delivery approaches to improving adaptive immune responses
Ou, B. S., Saouaf, O. M., Baillet, J., & Appel, E. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114401 · Cited by 94
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Bian, X., Zhou, L., Luo, Z., Liu, G., Hang, Z., Li, H., Li, F., & Wen, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c11858 · Cited by 101
mRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 98
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
Kalita, T., Dezfouli, S. A., Pandey, L. M., & Uludağ, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112520 · Cited by 90
Zhang, J., Wang, S., Guo, X., Lu, Y., Liu, X., Jiang, M., Li, X., Qin, B., Luo, Z., Liu, H., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c05408 · Cited by 89
Ripoll, M., Bernard, M., Vaure, C., Bazin, E., Commandeur, S., Perkov, V., Lemdani, K., Nicolaï, M., Bonifassi, P., Kichler, A., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121570 · Cited by 89
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 104
Paloncýová, M., Čechová, P., Šrejber, M., Kührová, P., & Otyepka, M. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c03109 · Cited by 82
Vaidya, A., Moore, S., Chatterjee, S., Guerrero, E. D., Kim, M., Farbiak, L., Dilliard, S. A., & Siegwart, D. J. (2024) · Advanced Materials · doi:10.1002/adma.202313791 · Cited by 89
Kis, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020430 · Cited by 84
Catenacci, L., Rossi, R., Sechi, F., Buonocore, D., Sorrenti, M., Perteghella, S., Peviani, M., & Bonferoni, M. C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121521 · Cited by 86
The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA
Barbieri, B. D., Peeler, D. J., Samnuan, K., Day, S., Hu, K., Sallah, H., Tregoning, J. S., McKay, P. F., & Shattock, R. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.016 · Cited by 85
Self-Amplifying RNA Approach for Protein Replacement Therapy
Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76
Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA
Friis, K. P., Gracin, S., Oag, S., Leijon, A., Sand, E., Lindberg, B., Lázaro‐Ibáñez, E., Lindqvist, J., Whitehead, K. A., & Bak, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.031 · Cited by 79
Ragelle, H., Rahimian, S., Guzzi, E. A., Westenskow, P. D., Tibbitt, M. W., Schwach, G., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113990 · Cited by 76
Zhang, R., Shao, S., Piao, Y., Xiang, J., Wei, X., Zhang, Z., Zhou, Z., Tang, J., Qiu, N., Xu, X., et al. (2023) · Advanced Materials · doi:10.1002/adma.202303614 · Cited by 72
A preparation method for mRNA-LNPs with improved properties
Geng, C., Zhou, K., Yan, Y., Li, C., Ni, B., Liu, J., Wang, Y., Zhang, X., Wang, D., Lv, L., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.017 · Cited by 71
Size and Charge Characterization of Lipid Nanoparticles for mRNA Vaccines
Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04778 · Cited by 75
Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles
Henderson, M. I., Eygeris, Y., Jozić, A., Herrera‐Barrera, M., & Sahay, G. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00587 · Cited by 71
Self-citationA lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 69
The Delivery of mRNA Vaccines for Therapeutics
Nitika, Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12081254 · Cited by 71
Bernard, M., Bazin, E., Petiot, N., Lemdani, K., Commandeur, S., Verdelet, C., Margot, S., Perkov, V., Ripoll, M., Garinot, M., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.004 · Cited by 63
mRNA therapies: Pioneering a new era in rare genetic disease treatment
Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 62
Recent Advances in the Noninvasive Delivery of mRNA
Qin, M., Du, G., & Sun, X. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00493 · Cited by 62
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles
Delehedde, C., Even, L., Midoux, P., Pichon, C., & Perche, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070945 · Cited by 60
Novel Perspectives towards RNA-Based Nano-Theranostic Approaches for Cancer Management
Arshad, R., Fatima, I., Sargazi, S., Rahdar, A., Karamzadeh-Jahromi, M., Pandey, S., Diez-Pascual, A. M., & Bilal, M. (2021) · Nanomaterials · doi:10.3390/nano11123330 · Cited by 59
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 61
Le, N. D., Nguyễn, B. L., Patil, B. R., Chun, H., Kim, S., Nguyen, T. O. O., Mishra, S. K., Tandukar, S., Chang, J., Kim, D. Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c13039 · Cited by 59
Self-citationRNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 64
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 58
Application of lipid-based nanoparticles in cancer immunotherapy
Zhang, Z., Yao, S., Hu, Y., Zhao, X. B., & Lee, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967505 · Cited by 58
Monkeypox virus: An emerging epidemic
Aljabali, A. A. A., Obeid, M. A., Nusair, M. B., Hmedat, A., & Tambuwala, M. M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105794 · Cited by 60
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Wang, B., Tang, M., Chen, Q., Ho, W., Teng, Y., Xiong, X., Jia, Z., Li, X., Xu, X., & Zhang, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c00063 · Cited by 60
Rakotoarisoa, M., Angelov, B., Espinoza, S., Khakurel, K. P., Bizien, T., Drechsler, M., & Angelova, A. (2021) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.1c04706 · Cited by 57
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization
Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 57
Innate and adaptive immune responses toward nanomedicines
Viana, I. M. D. O., Roussel, S., Defrêne, J., Lima, E. M., Barabé, F., & Bertrand, N. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.022 · Cited by 57
mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo
Cao, Q., Fang, H., & Tian, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122628 · Cited by 56
Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components
Wu, F., Li, N., Xiao, Y., Palanki, R., Yamagata, H. M., Mitchell, M. J., & Han, X. (2025) · Small Methods · doi:10.1002/smtd.202401632 · Cited by 64
Ultrasonic particles: An approach for targeted gene delivery
Walsh, A. P. G., Gordon, H. N., Peter, K., & Wang, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113998 · Cited by 58
An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics
Ingle, R. G., & Fang, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041158 · Cited by 57
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 60
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 54
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma
Liu, Y., Zhang, D., An, Y., Sun, Y., Li, J., Zheng, M., Zou, Y., & Shi, B. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101790 · Cited by 52
Zhou, Q., Liu, Q., Wang, Y., Chen, J., Schmid, O., Rehberg, M., & Yang, L. (2024) · Advanced Science · doi:10.1002/advs.202308659 · Cited by 51
Polymeric materials for immune engineering: Molecular interaction to biomaterial design
Soni, S. S., & Rodell, C. B. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.016 · Cited by 52
Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines
Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 51
Cordeiro, A. S., Patil‐Sen, Y., Shivkumar, M., Patel, R., Khedr, A., & Elsawy, M. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122091 · Cited by 54
New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention
Solanki, R., Shankar, A., Modi, U., & Patel, S. (2023) · Materials Today Chemistry · doi:10.1016/j.mtchem.2023.101478 · Cited by 50
Messenger RNA chromatographic purification: advances and challenges
Xue, F., Su, Z. G., Cheng, Y., Ma, G., & Zhang, S. (2023) · Journal of Chromatography A · doi:10.1016/j.chroma.2023.464321 · Cited by 50
Oyama, R., Ishigame, H., Tanaka, H., Tateshita, N., Itazawa, M., Imai, R., Nishiumi, N., Kishikawa, J.-I., Kato, T., Anindita, J., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c02251 · Cited by 49
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 52
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
mRNA Vaccines: Why Is the Biology of Retroposition Ignored?
Domazet‐Lošo, T. (2022) · Genes · doi:10.3390/genes13050719 · Cited by 47
Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation
Kim, J., Jozić, A., Bloom, E., Jones, B., Marra, M., Murthy, N. T. V., Eygeris, Y., & Sahay, G. (2024) · ACS Nano · doi:10.1021/acsnano.4c00768 · Cited by 52
Self-citation
Metadata
- Authors
- Kim, J., Eygeris, Y., Gupta, M., & Sahay, G.
- Affiliations
- Oregon State University (US)
- Corresponding author
- Sahay, Gaurav
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 170
- Pages
- 83-112
- ISSN
- 0169-409X (ISSN-L)
- PMC
- PMC7837307
- OpenAlex
- W3119364115
- Cited by
- 514
- References
- 318
- Citations by year
- 2026: 49 · 2025: 119 · 2024: 105 · 2023: 90 · 2022: 98 · 2021: 53
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Eye Institute
- Cystic Fibrosis Foundation
- National Heart and Lung Institute
- National Heart, Lung, and Blood Institute (1R21EY031066, 5R01HL146736, SAHAY19XX0)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- mRNA vaccines, self-assembly, mRNA delivery, lipid nanoparticles, COVID-19 vaccines, route of administration, immune activation, gene therapy, vaccine design
- MeSH terms
- COVID-19 Vaccines, mRNA Vaccines, Animals, Humans, RNA, Messenger, Vaccines, Synthetic, Drug Design, Gene Transfer Techniques, Nanotechnology, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
